SECOND GENOME
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.secondgenome.com/
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Second Genome
- Target Recruit Count
- 9
- Registration Number
- NCT03676231
- Locations
- 🇺🇸
Second Genome Clinical Site 405, Chandler, Arizona, United States
🇺🇸Second Genome Clinical Site 406, Tucson, Arizona, United States
🇺🇸Second Genome Clinical Site 403, Panorama City, California, United States
News
Basecamp Research Secures $60M and Partners with Broad Institute to Advance AI-Driven Genetic Medicine
Basecamp Research has raised $60 million in Series B funding and established a collaboration with the Broad Institute's David Liu lab to develop programmable genetic medicines.